Zhongyuan Union Cell & Gene Eng

What Zhongyuan Union Cell & Gene Eng does

Zhongyuan Union Cell & Gene Engineering Corp., Ltd. (中源协和细胞基因工程股份有限公司, SSE: 600645) is a Tianjin-headquartered, publicly listed Chinese precision medicine conglomerate operating across three integrated business segments: precision prevention (cell storage), precision diagnosis (in vitro diagnostics and life science reagents), and cell therapy (stem cell drugs and CAR-T). The company runs China's first Ministry of Health-approved cord blood bank — Tianjin Cord Blood Hematopoietic Stem Cell Bank (licensed 2002, 卫脐血干细胞库字[2002]第002号) — under a 20-province cell resource storage network covering newborn cord blood/mesenchymal/placental stem cells and adult immune/adipose/dental pulp stem cells, marketed to families via the 脐荐康LifeBank WeChat platform and a national hotline (400-6688-298).

The precision diagnosis segment is built on wholly-owned subsidiaries: Zhongshan Golden Bridge (中杉金桥, pathology immunohistochemistry with 31-province sales coverage and Ultra 60 Plus/UltraPATH 30N automated stainers), OriGene (傲锐东源, 400,000+ gene clones, 41,000+ recombinant proteins, 160,000+ antibodies with US/German operations), Shanghai Zhicheng (IVD reagents in biochemical/immune/POCT categories), and Zhongyuan Weikang (中源维康, China's first NMPA-approved time-of-flight mass spectrometry tumor companion diagnostic kit for EGFR/KRAS/BRAF/ERBB2/PIK3CA, March 2026). The cell therapy segment is anchored by Wuhan Optics Valley Zhongyuan Pharmaceutical (武汉光谷中源药业), which holds 11 IND approvals for VUM02 and VUM03 human umbilical cord MSC injections — ranking #1 in China per CDE statistics — plus an equity stake in Heyuan Bio (合源生物), whose Yuanshengda (纳基奥仑赛注射液) became China's first domestically developed CD19 CAR-T product (NMPA approved November 2023 for B-cell ALL, expanded to lymphoma in November 2025). A subsidiary also filed the first US FDA DMF for a Chinese iPSC cell line in February 2026.

Revenue is generated through four streams: recurring cell storage subscriptions (B2C, multi-year contracts), one-time IVD reagent and equipment sales (B2B via subsidiaries covering 31 provinces), global research reagent distribution via OriGene (B2B), and emerging cell therapy revenue from CAR-T commercialization and MSC clinical trials. Reported financials (CNY) show revenue of ¥1.455B in 2025, ¥1.585B in 2024, ¥1.589B in 2023, and ¥1.555B in 2022; 2025 EBITDA grew to ¥336M while net income held at ¥114M. The company employs 1,001-5,000 people and was founded in 1993.

Name

Zhongyuan Union Cell & Gene Eng

Legal name

中源协和细胞基因工程股份有限公司

Website

https://vcanbio.com

Company type

Public

Founded year

1993

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Zhongyuan Union Cell & Gene Engineering (SSE: 600645) is a Tianjin-based Chinese precision medicine conglomerate operating cell storage across 20 provinces, IVD/pathology diagnostics, and a top-ranked MSC stem cell drug pipeline, with equity exposure to China's first domestically developed CD19 CAR-T product.

Ownership category

akta.pro rank

Product category

Precision Medicine / Biotechnology

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)

akta.pro secondary industries

Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Cell storage services
• In vitro diagnostics
• Stem cell therapy
• Cord blood banking
• Biological research reagents

Headquarters

HQ city

Tianjin

HQ country

China

HQ region

Asia

Offices8 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Cell Storage Services: Recurring revenue from cord blood, cord mesenchymal stem cell, placental stem cell storage for newborns, and immune cell, adipose stem cell, dental pulp stem cell storage for adults. Services priced annually with multi-year contracts. National network across 20 provinces provides competitive advantage.
2. In Vitro Diagnostics Products & Equipment: One-time and recurring revenue from sale of diagnostic reagents (biochemical, immunological, POCT categories), diagnostic equipment, pathology immunohistochemistry antibodies, staining reagents, and automated equipment. Includes consumables and reagents for research and clinical use. Subsidiaries 中杉金桥, 傲锐东源, 上海执诚, 中源维康 each contribute.
3. Stem Cell Drug Development & Clinical Services: Revenue from stem cell drug clinical trials, IND filings, and commercialization. VUM02 and VUM03 injections with 11 approved INDs lead the domestic MSC drug field. CAR-T product 源瑞达 commercialized through affiliated company 合源生物 (approved 2023).
4. Scientific Research Reagents: Sale of biological gene, protein, antibody research reagent products via OriGene to global life science customers, including CRISPR, RNA interference, viral vector systems.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels9 records

Core offering

Zhongyuan Xiehe (VCANBIO, SSE: 600645) operates a precision medicine platform spanning three business segments: cell detection/preparation and storage (cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental stem cells, adult immune cells, adipose and dental pulp stem cells) provided through a 20-province nationwide network of comprehensive cell banks; in vitro diagnostics (IVD raw materials, reagents, equipment, immunohistochemistry antibodies, automated staining systems) manufactured by subsidiaries including Zhongshan Golden Bridge, OriGene, and Shanghai Zhicheng; and cell therapy drug development including VUM02 and VUM03 mesenchymal stem cell injections, the CD19 CAR-T product Yuankuijia (NaxAcillin Injection), and iPSC cell lines, distributed via B2B channels to hospitals, research institutions, and global life science customers.

Differentiator

Problem solved

Functional benefit

Brands

• VUM02注射液: Human umbilical cord-derived mesenchymal stromal cell injection with 10 indications approved for IND, including idiopathic pulmonary fibrosis and acute graft-versus-host disease.
• VUM03注射液
• 源瑞达 (纳基奥仑赛注射液)
• 中杉金桥
• 傲锐东源 (OriGene)
• 上海执诚
• 中源维康
• 天津市脐血库

Products and services

• Tianjin Cord Blood Hematopoietic Stem Cell Storage Service (天津市脐带血造血干细胞存储) Long-term cryopreservation of newborn cord blood hematopoietic stem cells for family health banking; enables potential future therapeutic use including hematopoietic stem cell transplantation. Targets expecting families across 20 Chinese provinces.
• Comprehensive Stem Cell and Immune Cell Storage Services (新生儿/成人干细胞存储服务) Subscription-based long-term storage of cord mesenchymal stem cells, placental stem cells, adult immune cells, adipose mesenchymal stem cells, and dental pulp mesenchymal stem cells for family health insurance and personalized regenerative medicine use.
• VUM02 Human Umbilical Cord Mesenchymal Stromal Cell Injection (VUM02注射液) Stem cell drug targeting 10 indications including decompensated liver cirrhosis, idiopathic pulmonary fibrosis, acute-on-chronic liver failure, ARDS, severe COVID-19, acute graft-versus-host disease, systemic sclerosis, ulcerative colitis, severe pneumonia, and post-pneumonia progressive pulmonary fibrosis. Ranked #1 in China for MSC drug IND approvals by CDE statistics.
• VUM03 Stem Cell Injection (VUM03注射液) Stem cell drug for inactive/mild active Crohn's disease with complex perianal fistula. Clinical trial application accepted by NMPA.
• Yuankuijia (源瑞达) CD19 CAR-T Cell Therapy (纳基奥伦赛注射液) Autologous CD19-directed CAR-T cell therapy for adult relapsed/refractory B-cell acute lymphoblastic leukemia and lymphoma indications. Targets hospitals treating relapsed/refractory hematological malignancy patients.
• EGFR/KRAS/BRAF/ERBB2/PIK3CA Gene Mutation Time-of-Flight Mass Spectrometry Tumor Companion Diagnostic Kit (飞行时间质谱法肿瘤伴随诊断试剂盒) Tissue-based companion diagnostic kit for detecting EGFR, KRAS, BRAF, ERBB2, and PIK3CA gene mutations, enabling targeted therapy selection for cancer patients. Targets hospital clinical laboratories and pathology departments.
• iPSC Cell Lines (诱导多能干细胞/iPSC) Induced pluripotent stem cell lines for pharmaceutical R&D, cell therapy drug development, and clinical applications. Available to global biopharmaceutical customers and research institutions.
• Ultra 60 Plus and UltraPATH 30N Automated Immunohistochemistry Staining Systems (Ultra 60 Plus & UltraPATH 30N 全自动免疫组化染色系统)
• OriGene Gene Clones, Recombinant Proteins, and Antibody Research Reagent Catalog (傲锐东源 OriGene) Biological research reagent catalog covering gene clones, recombinant proteins, antibodies, CRISPR tools, RNA interference products, and viral vectors for life science research. Targets global research institutions and biopharma companies worldwide through US, Germany, and China operations.
• IVD Diagnostic Reagents (biochemical, immunological, POCT)
• Human Dental Pulp Mesenchymal Stem Cell Injection (人牙髓间充质干细胞注射液) Stem cell therapy drug for chronic periodontitis treatment. Co-developed with Capital Medical University; IND approved. Targets dental and periodontal disease patients.

Quantifiable outcome

• Tianjin Cord Blood Bank: 4,000+ cord blood units provided for clinical use over 25 years of safe operation (as of April 2026)
• +5 more outcomes

Named customers8 records

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

14 partnerships are on record, tiered core and secondary.

• 中国医学科学院血液病医院（中国医学科学院血液学研究所）coreStrategic or Co-development Partner · 1 January 2015Comprehensive strategic partnership established in 2015 including overseas talent introduction, diagnostic reagent R&D, CAR-T technology translation, stem cell clinical research, and regional cell preparation center construction. The 华苑院区 of the hospital was completed on the company campus in 2018. Multiple fruitful outcomes achieved including CAR-T product development and stem cell clinical projects.
• 世界卫生组织亚洲脐带血库联盟 (WHO Asia Pacific Cord Blood Bank Alliance)coreOthersTianjin Cord Blood Bank is a member of the WHO Asia Pacific Cord Blood Bank Alliance, providing international recognition and standards benchmarking for cord blood banking operations.
• 协和干细胞基因工程有限公司coreStrategic or Co-development PartnerWholly-owned subsidiary specializing in cord blood banking and stem cell R&D. Developed iPSC cell lines that received US FDA DMF filing in 2026 — China's first. Operates the Tianjin Cord Blood Bank (25 years of safe operation, 4,000+ clinical applications).
• 武汉光谷中源药业有限公司 (Wholly-owned subsidiary)coreStrategic or Co-development PartnerWholly-owned subsidiary developing stem cell drug pipeline — VUM02注射液 (10 INDs) and VUM03注射液 (1 IND), leading China's MSC drug field with 11 total INDs. Led by CEO 张宇.
• 北京三有利和泽生物科技有限公司coreStrategic or Co-development PartnerCompany holds equity stake. Co-developed with 首都医科大学 China's first dental pulp mesenchymal stem cell injection drug for chronic periodontitis. Phase II clinical trial completed enrollment in 2024.
• 合源生物科技股份有限公司coreStrategic or Co-development PartnerCompany holds equity stake in Heyuan Bio. Heyuan's CD19 CAR-T product 源瑞达 (纳基奥仑赛注射液) became China's first domestically-developed CAR-T product approved by NMPA (November 2023). Lymphoma indication approved November 2025, Macau approval November 2024. Board member Zhou Yuru represents the company.
• 中杉金桥生物技术有限公司 (Beijing Zhongshan Golden Bridge)coreChannel Partner/ Reseller/ DistributorSubsidiary (since 1991, over 30 years) specializing in pathological diagnostics. Provides 'reagent + instrument' dual-core products. Ultra 60 Plus and UltraPATH 30N automated immunohistochemistry staining systems. Sales and service network covering 31 provinces/municipalities.
• 傲锐东源 OriGene (无锡傲锐东源 & OriGene US/Germany)coreChannel Partner/ Reseller/ DistributorGlobal gene/protein/antibody products company with US (founded 1996, Maryland), China (Wuxi, established 2010), and Germany operations. Product catalog: 400,000+ gene clones, 41,000+ proteins, 160,000+ antibodies. Serves global life science research market.
• 上海执诚生物科技有限公司secondaryChannel Partner/ Reseller/ DistributorSubsidiary engaging in IVD equipment and reagent R&D, production, and sales. Products cover biochemical, immunological, POCT categories (liver, kidney, lipid, blood glucose). Participates in regional inspection center construction and hospital centralized procurement.
• 中源维康基因科技有限公司secondaryTechnology or IntegrationSubsidiary developing nucleic acid mass spectrometry genetic testing platform. Tissue diagnostic kit (EGFR/KRAS/BRAF/ERBB2/PIK3CA) approved by NMPA — China's first time-of-flight mass spectrometry companion diagnostic. Blood diagnostic kit under clinical trial per NMPA guidelines.
• 协和华东干细胞基因工程有限公司secondaryChannel Partner/ Reseller/ DistributorSubsidiary operating Zhejiang Province Cord Blood Stem Cell Bank (浙江省脐带血造血干细胞库的运营单位之一).
• 和泽生物科技有限公司secondaryChannel Partner/ Reseller/ DistributorSubsidiary managing cell storage operations in various regions. Multiple subsidiary companies under its umbrella operating across different provinces.
• 海南梅赛尔医院secondaryStrategic or Co-development PartnerVUM02 injection liver cirrhosis clinical transformation officially launched at Hainan Mercy Hospital in Boao Lecheng in 2025. First stem cell therapy clinical transformation project at this hospital.
• Vcan Bio USA Co., Ltd. / Vcanbio Center For Translational Biotechnology Corp.secondaryTechnology or IntegrationUS-based subsidiaries for biotechnology translational research and development. Established 2016 as part of globalization strategy. Also houses SDIX antibody production R&D base.

Scale indicators12 records

Recent moves11 records

Expansion highlights8 records

Broad incumbents

• GenScript Biotech: Hong Kong-listed Chinese life science tools and cell therapy company (Legend Biotech parent for Carvykti CAR-T). Overlaps with Zhongyuan Xiehe across research reagent supply, cell therapy development, and biopharma services.
• WuXi AppTec: Largest Chinese CRO/CDMO with global operations across biologics, cell therapy, and genomic services. Comparable through its cell therapy CDMO capabilities and broad life sciences research reagent offerings.
• BGI Genomics: China's largest genomics and molecular diagnostics company with companion diagnostics, genetic testing, and a cell therapy arm. Comparable in the IVD/companion diagnostics and cell bank segments, with broader scale and diversification.
• Fosun Pharma: Large diversified Chinese pharma with significant cell therapy, IVD, and biotech investments. Provides a comparable platform model spanning pharma, diagnostics, and innovative biologics across China and global markets.
• Mindray Medical: Largest Chinese in-vitro diagnostics and medical device company offering biochemistry, immunology, POCT reagents and automated equipment. Comparable to Zhongyuan Xiehe's IVD subsidiaries (Zhongshan Golden Bridge, Shanghai Zhicheng) at a much larger scale.

Direct peers

• CARsgen Therapeutics: Hong Kong-listed Chinese CAR-T developer with multiple approved/clinical-stage autologous CAR-T therapies (e.g., zevorcabtagene autoleucel for multiple myeloma). Directly comparable as a domestic CAR-T competitor with overlapping hematological malignancy indications.
• Beike Biotechnology: Chinese cell therapy company offering adult stem cell storage and stem cell drug development for degenerative diseases. Directly comparable in the cord blood/mesenchymal stem cell storage and therapy segment where Zhongyuan Xiehe leads China.
• JW Therapeutics: Chinese CAR-T cell therapy company that has commercialized Carteyva (relmacabtagene autoleucel), a CD19 CAR-T approved in China for relapsed/refractory B-cell lymphoma. Directly comparable to Zhongyuan Xiehe's CAR-T commercialization arm via Heyuan Bio, competing in the same autologous CAR-T market segment.
• Da An Gene (Kingmed Diagnostics subsidiary): Chinese molecular diagnostics and IVD company specializing in PCR, sequencing, and companion diagnostics. Comparable to Zhongyuan Weikang's time-of-flight mass spec tumor CDx kit in the precision oncology diagnostic space.

Others

• Pharmaron: Chinese CRO/CDMO providing drug discovery, preclinical, and clinical development services. Comparable as a Chinese-headquartered life science services platform with adjacent biomanufacturing capabilities relevant to cell therapy development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zhongyuan Union Cell & Gene Eng